Cell Death Pathways in 4R-Tauopathies

Cell Death Pathways in 4R-Tauopathies

Cell death pathways represent critical final common mechanisms in 4-repeat (4R) tauopathies, where the progressive accumulation of hyperphosphorylated 4R tau in neurons and glia ultimately leads to neurodegeneration. Understanding how apoptosis and necroptosis contribute to neuronal loss in progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) provides essential insights into disease pathogenesis and identifies potential therapeutic targets. While these diseases share the common feature of 4R tau aggregation, the specific cell death pathways activated and their relative contributions vary depending on the tau strain, cellular vulnerability, and regional pathology patterns.

Overview of Cell Death in 4R-Tauopathies

The 4R-tauopathies comprise a group of neurodegenerative disorders characterized by the preferential accumulation of tau isoforms containing four microtubule-binding repeats (4R tau)[@goedert2018]. This stands in contrast to Alzheimer's disease, where both 3R and 4R tau isoforms aggregate in neurofibrillary tangles. The specific inclusion of 4R tau isoforms arises from alternative splicing of exon 10 of the MAPT gene, which is regulated by various splicing factors and can be influenced by mutations in FTDP-17[@baker1999].

Common Pathological Features

Cell Death Pathways in 4R-Tauopathies

Cell death pathways represent critical final common mechanisms in 4-repeat (4R) tauopathies, where the progressive accumulation of hyperphosphorylated 4R tau in neurons and glia ultimately leads to neurodegeneration. Understanding how apoptosis and necroptosis contribute to neuronal loss in progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), argyrophilic grain disease (AGD), globular glial tauopathy (GGT), and frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17) provides essential insights into disease pathogenesis and identifies potential therapeutic targets. While these diseases share the common feature of 4R tau aggregation, the specific cell death pathways activated and their relative contributions vary depending on the tau strain, cellular vulnerability, and regional pathology patterns.

Overview of Cell Death in 4R-Tauopathies

The 4R-tauopathies comprise a group of neurodegenerative disorders characterized by the preferential accumulation of tau isoforms containing four microtubule-binding repeats (4R tau)[@goedert2018]. This stands in contrast to Alzheimer's disease, where both 3R and 4R tau isoforms aggregate in neurofibrillary tangles. The specific inclusion of 4R tau isoforms arises from alternative splicing of exon 10 of the MAPT gene, which is regulated by various splicing factors and can be influenced by mutations in FTDP-17[@baker1999].

Common Pathological Features

Despite their classification as distinct diseases, 4R-tauopathies share several key pathological features that trigger cell death pathways:

• Hyperphosphorylated tau accumulation: Excessively phosphorylated tau protein loses its ability to bind microtubules and instead forms toxic oligomers and filaments
• Tau filament formation: Different tau strains (structural variants) characterize different diseases, influencing their pathological properties and cellular vulnerability[@spillantini2000]
• Neuronal loss: Progressive neuronal death in region-specific patterns underlies the clinical phenotypes
• Glial pathology: Astrocytic and oligodendroglial tau inclusions contribute to neurodegeneration

Cell Death Pathway Activation

Two primary programmed cell death pathways contribute to neurodegeneration in 4R-tauopathies:

The relative activation of these pathways differs across the various 4R-tauopathies and even among different neuronal populations within a single disease, creating a complex landscape of cell death mechanisms that must be understood to develop effective neuroprotective therapies.

Apoptosis Pathways in 4R-Tauopathies

Apoptosis in 4R-tauopathies involves both intrinsic (mitochondrial) and extrinsic (death receptor) pathways, with evidence suggesting that both pathways contribute to neuronal loss in varying degrees depending on the specific disease and disease stage.

Intrinsic (Mitochondrial) Apoptosis

Bcl-2 Family Dysregulation

The Bcl-2 family of proteins serves as critical regulators of the intrinsic apoptotic pathway, functioning as either pro-apoptotic or anti-apoptotic molecules that control mitochondrial outer membrane permeabilization (MOMP)[@chen2014]. In 4R-tauopathies, dysregulation of these proteins contributes to mitochondrial dysfunction and apoptosis.

Anti-apoptotic members (elevated as compensatory response):

• Bcl-2: Often upregulated in 4R-tauopathy brains as a neuroprotective response, though this compensation is ultimately insufficient
• Bcl-xL: Highly expressed in neurons and can be induced by tau pathology
• Mcl-1: Rapidly turning over protein with essential role in neuronal survival

• Bax: Translocates to mitochondria upon apoptotic stimulation, leading to cytochrome c release
• Bak: Directly induces MOMP in the outer mitochondrial membrane
• BH3-only proteins (Bim, Puma, Noxa): Activated by various cellular stresses including tau toxicity

Mitochondrial Dysfunction

Tau pathology directly impairs mitochondrial function through multiple mechanisms[@feinstein2019]:

• Tau accumulation in mitochondria: Hyperphosphorylated tau localizes to mitochondria, impairing electron transport chain function
• Reduced mitochondrial dynamics: Tau disrupts the balance between fission and fusion, leading to fragmented mitochondria
• ATP depletion: Impaired oxidative phosphorylation reduces cellular energy reserves
• Increased ROS production: Mitochondrial dysfunction leads to elevated reactive oxygen species
• Calcium dysregulation: Mitochondrial calcium handling is compromised, leading to cytosolic calcium overload

Cytochrome c Release and Apoptosome Formation

When MOMP occurs in 4R-tauopathies, cytochrome c is released from the mitochondrial intermembrane space, binding to Apaf-1 and ATP to form the apoptosome[@raitano2015]. This complex recruits and activates procaspase-9, initiating the caspase cascade that leads to executioner caspase activation and cell death.

Extrinsic (Death Receptor) Apoptosis

Death Receptor Expression

Neurons in 4R-tauopathies exhibit altered expression of death receptors:

• Fas (CD95): Elevated in PSP and CBD brains, particularly in affected brain regions
• TNFR1 (TNF Receptor 1): Increased expression contributes to sensitivity to TNF-α-mediated apoptosis
• TRAIL Receptors: Variable expression across different 4R-tauopathies

Caspase-8 Activation

Caspase-8 activation at the death-inducing signaling complex (DISC) can directly activate executioner caspases or cleave Bid to tBid, linking extrinsic to intrinsic apoptosis. This cross-talk amplifies the apoptotic signal in tauopathy neurons.

Caspase Activation Patterns

Multiple caspases are activated in 4R-tauopathies, each contributing to different aspects of neuronal death:

Caspase-3

The major executioner caspase, caspase-3 is consistently activated in 4R-tauopathies[@colombo2019]:

• PSP: Elevated caspase-3 activity in subthalamic nucleus and brainstem nuclei
• CBD: Prominent in affected cortical regions and basal ganglia
• AGD: Detected in neurons with argyrophilic grains
• GGT: Activated in neurons with globular inclusions
• FTDP-17: Variable depending on specific MAPT mutation

• PARP (DNA repair enzyme)
• Gelsolin (cytoskeletal protein)
• ICAD (endonuclease inhibitor)

Caspase-6

Caspase-6 is particularly relevant in tauopathies due to its ability to cleave tau protein[@davis2018]:

• PSP: Caspase-6 cleavage of tau generates neurotoxic fragments that seed aggregation
• CBD: Similar pattern with tau cleavage products detected
• AGD: Caspase-cleaved tau fragments in affected neurons
• GGT: Tau cleavage contributes to aggregation of 4R tau
• FTDP-17: Mutant tau may be more susceptible to caspase cleavage

• Are more aggregation-prone than full-length tau
• May act as seeds for tau fibrilization
• Contribute to prion-like spreading of pathology

Caspase-9

Caspase-9 activation reflects engagement of the intrinsic apoptotic pathway[@martinez2019]:

• Activated in response to mitochondrial cytochrome c release
• Present in active form in PSP brain tissue
• Correlates with disease severity in multiple 4R-tauopathies

Caspase-8

Extrinsic pathway activation involves caspase-8[@kelley2019]:

• Activated at death receptor complexes
• Can initiate direct caspase-3 activation
• Provides cross-talk between extrinsic and intrinsic pathways

Disease-Specific Apoptosis Patterns

Progressive Supranuclear Palsy (PSP)

PSP demonstrates a characteristic pattern of apoptosis that correlates with its clinical phenotype[@tokutake2015]:

Affected Regions:

• Subthalamic nucleus (prominent neuronal loss)
• Brainstem nuclei (particularly the pedunculopontine nucleus)
• Cerebellar dentate nucleus
• Basal ganglia
• Frontal and prefrontal cortex

• Elevated Bax/Bcl-2 ratio in vulnerable regions
• Active caspase-3 and caspase-9
• Caspase-cleaved tau fragments in neurons
• Mitochondrial complex I deficiency
• p53 activation in affected neurons

• Certain neuronal populations (e.g., cholinergic neurons in NBM) show relative sparing
• Giant cortical neurons more susceptible than smaller interneurons
• Oligodendroglial apoptosis contributes to white matter pathology

Corticobasal Degeneration (CBD)

CBD exhibits apoptosis patterns reflecting its asymmetric cortical and basal ganglia pathology[@ishida2013]:

Affected Regions:

• Motor and premotor cortex (Betz cells particularly vulnerable)
• Basal ganglia (striatum and globus pallidus)
• Substantia nigra pars compacta
• Brainstem nuclei

• TDP-43 pathology intersects with apoptotic pathways
• Caspase-3 activation in affected cortical neurons
• Bcl-2 family dysregulation
• ER stress contributing to intrinsic apoptosis
• Distinct pattern of BH3-only protein activation

• Apoptosis in supporting glial cells contributes to disease
• Non-cell autonomous toxicity from activated glia
• Inflammatory cytokines amplify apoptotic signaling

Argyrophilic Grain Disease (AGD)

AGD shows a somewhat distinct apoptotic pattern, reflecting its characteristic pathology[@yoshida2019]:

Affected Regions:

• Limbic system (amygdala, hippocampus)
• Entorhinal cortex
• Temporal pole
• Septal nuclei

• Argyrophilic grains (4R tau) in affected neurons
• Less prominent caspase activation compared to PSP and CBD
• Predominantly slow progressive neuronal loss
• Moderate mitochondrial dysfunction

• Neurons with grains show signs of chronic stress
• Apoptosis occurs later in disease course
• Better preserved neurons may undergo other cell death forms

Globular Glial Tauopathy (GGT)

GGT demonstrates unique apoptosis mechanisms due to its glial-predominant pathology:

Affected Regions:

• White matter (globular glial inclusions)
• Cortical neurons (less affected than glia)
• Pyramidal tracts
• Brainstem

• Prominent oligodendroglial and astrocytic apoptosis
• 4R tau globular inclusions in glia
• Neuronal loss secondary to glial dysfunction
• Different caspase activation pattern (more caspase-1 in glia)

• Loss of myelin-producing oligodendrocytes
• Astrocyte dysfunction affecting neuronal support
• Secondary neuronal death from glial loss

Frontotemporal Dementia and Parkinsonism Linked to Chromosome 17 (FTDP-17)

FTDP-17 shows variable apoptosis patterns depending on the specific MAPT mutation[@matsuo1998]:

Affected Regions:

• Frontal and temporal cortex
• Anterior cingulate cortex
• Basal ganglia
• Substantia nigra

• P301L: Earlier onset, prominent apoptosis
• P301S: More aggressive phenotype
• Exon 10 mutations: Variable patterns
• Intronic mutations: Typical FTDP phenotype

• Mutant tau more prone to aggregation and apoptosis induction
• Altered splicing leading to 4R tau overexpression
• Enhanced caspase cleavage of mutant tau
• Variable Bcl-2 family expression based on mutation

Necroptosis Pathways in 4R-Tauopathies

Necroptosis has emerged as an important contributor to neurodegeneration in 4R-tauopathies, offering a potential explanation for the inflammatory component of these diseases and providing additional therapeutic targets.

The Necroptotic Machinery

Core Components

RIPK1 (Receptor-Interacting Protein Kinase 1)

• Serine/threonine protein kinase essential for necroptosis initiation
• Contains kinase domain, intermediate domain, and death domain
• Activated by death receptor engagement and various cellular stresses[@ofengeim2017]

• Essential for necroptosis execution
• Contains kinase domain and RHIM domain for protein interactions
• Forms amyloid-like filaments during necroptosis activation[@ito2016]

• Pseudokinase serving as the final effector of necroptosis
• Forms trimeric assemblies that pierce the plasma membrane
• Essential for membrane permeabilization and cell death[@wang2018]

Activation in 4R-Tauopathies

Tau-Induced Necroptosis

Tau pathology can activate necroptosis through multiple mechanisms[@kovacs2019]:

Evidence in PSP

RIPK1 and RIPK3 activation has been documented in PSP brain tissue[@onishi2019]:

• Phosphorylated RIPK1 in vulnerable neurons
• RIPK3 upregulation in affected regions
• MLKL activation correlating with disease severity
• Necrostatin-1 protection in PSP models

Evidence in CBD

CBD shows similar necroptosis activation patterns:

• Active RIPK1 in cortical and basal ganglia neurons
• RIPK3 expression in affected regions
• Interaction between tau and necroptotic machinery
• Potential therapeutic targeting opportunity

Evidence in Other 4R-Tauopathies

Less direct evidence exists for AGD, GGT, and FTDP-17, though:

• Common mechanistic pathways suggest necroptosis involvement
• Inflammatory component suggests necroptosis contribution
• Post-mortem studies show necroptosis markers in various tauopathies

Downstream Consequences

DAMP Release

Necroptotic cells release damage-associated molecular patterns (DAMPs) that propagate inflammation:

• HMGB1: Pro-inflammatory alarmin released from necrotic neurons
• ATP: Purinergic signaling activating microglia
• DNA fragments: Triggering interferon responses
• Tau oligomers: May seed further pathology

Neuroinflammation Amplification

The inflammatory consequences of necroptosis create feed-forward loops[@moriwaki2017]:

Therapeutic Implications

Necroptosis Inhibitors

| Compound | Target | Therapeutic Potential |
|----------|--------|---------------------|
| Necrostatin-1 | RIPK1 | Preclinical in PSP/CBD models |
| Necrostatin-1s | RIPK1 | Improved brain penetration |
| GSK'872 | RIPK3 | Research tool |
| MLKL inhibitors | MLKL | Early development |

Combination Approaches

Targeting both apoptosis and necroptosis may provide enhanced neuroprotection:

• Caspase inhibitors + necroptosis inhibitors
• Anti-inflammatory agents + cell death pathway blockers
• Tau-lowering therapies combined with neuroprotective strategies

Tau Strain Influence on Cell Death Pathways

Different 4R-tau strains (structural variants) influence cell death pathway activation, explaining the heterogeneity among 4R-tauopathies.

Structural Basis of Tau Strains

Cryo-EM studies have revealed distinct tau filament structures in different 4R-tauopathies[@bote2019]:

• PSP tau filaments: Characteristic "paperclip" conformation
• CBD tau filaments: Distinct from PSP
• AGD tau: Sparse grain-like aggregates
• GGT tau: Globular glial inclusions with distinct structure

Strain-Specific Cytotoxicity

Different tau strains activate distinct cell death pathways:

PSP strains:

• More efficient at triggering intrinsic apoptosis
• Stronger caspase-6 activation
• Mitochondrial dysfunction prominent

• Enhanced extrinsic pathway activation
• Greater inflammatory response
• Non-cell autonomous toxicity

• Slower, chronic cell death
• Less efficient apoptosis induction
• Longer disease duration

Implications for Therapeutics

Understanding strain-specific cell death mechanisms allows for personalized approaches:

• Strain-specific inhibitor targeting
• Tailored combination therapies
• Biomarker development for strain identification

Cross-Disease Comparison

Summary Table: Apoptosis in 4R-Tauopathies

| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| Intrinsic pathway | +++ | +++ | ++ | ++ | +++ |
| Extrinsic pathway | ++ | +++ | + | ++ | ++ |
| Caspase-3 | +++ | +++ | ++ | ++ | ++ |
| Caspase-6 | +++ | +++ | ++ | ++ | +++ |
| Caspase-9 | ++ | ++ | + | + | ++ |
| Bcl-2 family | Dysregulated | Dysregulated | Variable | Variable | Mutation-dependent |
| Mitochondrial dysfunction | +++ | +++ | ++ | ++ | +++ |

Summary Table: Necroptosis in 4R-Tauopathies

| Feature | PSP | CBD | AGD | GGT | FTDP-17 |
|---------|-----|-----|-----|-----|---------|
| RIPK1 activation | +++ | ++ | + | + | ++ |
| RIPK3 activation | ++ | ++ | + | + | + |
| MLKL activation | ++ | + | + | + | + |
| DAMP release | +++ | +++ | ++ | ++ | ++ |
| Inflammatory component | +++ | +++ | ++ | ++ | +++ |
| Necrostatin benefit | ++ | ++ | + | + | ++ |

Mechanistic Model

Cross-Links

• [Apoptosis Pathway in Neurodegeneration](/mechanisms/apoptosis)
• [Necroptosis Pathway in Neurodegeneration](/mechanisms/necroptosis)
• [4R Tauopathy Mechanisms](/mechanisms/4r-tauopathy-mechanisms)
• [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
• [Cortico-basal Degeneration](/diseases/corticobasal-degeneration)
• [Argyrophilic Grain Disease](/diseases/argyrophilic-grain-disease)
• [Globular Glial Tauopathy](/diseases/globular-glial-tauopathy)
• [FTDP-17](/diseases/ftdp-17)
• [Tau Protein](/proteins/tau)
• [MAPT Gene](/genes/mapt)
• [Caspase-3](/genes/casp3)
• [Caspase-6](/genes/casp6)
• [RIPK1 Gene](/genes/ripk1)
• [RIPK3 Gene](/genes/ripk3)
• [MLKL Gene](/genes/mlkl)
• [Bcl-2 Gene](/genes/bcl2)
• [Bax Gene](/genes/bax)

See Also

• [Alzheimer's Disease Cell Death](/mechanisms/apoptosis-alzheimers-disease)
• [Parkinson's Disease Cell Death](/mechanisms/apoptosis-parkinsons-disease)
• [Tau Phosphorylation Mechanisms](/mechanisms/tau-ptm-4r-tauopathies)
• [Tau Aggregation Kinetics](/mechanisms/tau-aggregation-kinetics-4r-tauopathies)
• [Neuroinflammation in 4R-Tauopathies](/mechanisms/neuroinflammation-4r-tauopathies)
• [Mitochondrial Dysfunction in 4R-Tauopathies](/mechanisms/mitochondrial-dysfunction-4r-tauopathies)

External Links

• [PubMed](https://pubmed.ncbi.nlm.nih.gov/)
• [KEGG Pathways](https://www.genome.jp/kegg/pathway.html)
• [CSTDP Foundation](https://www.psp.org/)

References